Bruno Dubois
YOU?
Author Swipe
View article: Prediction-powered inference for clinical trials: application to linear covariate adjustment
Prediction-powered inference for clinical trials: application to linear covariate adjustment Open
Prediction-powered inference (PPI) (Angelopoulos et al., Science 382(6671):669-674, 2023) and its subsequent development called PPI++ (Angelopoulos et al., 2023) provide a novel approach to standard statistical estimation, leveraging machi…
View article: Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC Open
Comprehensive guidance is provided on the potential implementation of anti-amyloid antibody therapies in Europe following possible approval. Emphasis is placed on the necessity of regularly updating recommendations as new evidence emerges …
View article: The International Working Group recommendations on cognitively unimpaired individuals
The International Working Group recommendations on cognitively unimpaired individuals Open
View article: Introduction
Introduction Open
View article: Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities Open
A European Task Force has recently developed and published the concept and protocols for the setup of the innovative health offer of Brain Health Services for the secondary prevention of dementia and cognitive impairment (dBHS). dBHS are o…
View article: Development of a diagnostic checklist to identify functional cognitive disorder versus other neurocognitive disorders
Development of a diagnostic checklist to identify functional cognitive disorder versus other neurocognitive disorders Open
Background Functional cognitive disorder (FCD) poses a diagnostic challenge due to its resemblance to other neurocognitive disorders and limited biomarker accuracy. We aimed to develop a new diagnostic checklist to identify FCD versus othe…
View article: Prediction-powered Inference for Clinical Trials: application to linear covariate adjustment
Prediction-powered Inference for Clinical Trials: application to linear covariate adjustment Open
Prediction-powered inference (PPI) and its subsequent development called PPI++ provide a novel approach to standard statistical estimation leveraging machine learning systems to enhance unlabeled data with predictions. We use this paradigm…
View article: Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers
Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers Open
The relationship between cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease and neurodegenerative effects is not fully understood. This study investigates neurodegeneration patterns across CSF Alzheimer’s disease biomarker groups,…
View article: Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation Open
Importance: Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer Association (AA) criteria for AD furthers this direction. Howev…
View article: Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial Open
Summary Background Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer’s disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown.…
View article: Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation Open
Importance Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer’s Association (AA) criteria for AD furthers this direction. Howe…
View article: The memory binding test can anticipate Alzheimer’s disease diagnosis at an early preclinical stage: a longitudinal study in the INSIGHTpreAD cohort
The memory binding test can anticipate Alzheimer’s disease diagnosis at an early preclinical stage: a longitudinal study in the INSIGHTpreAD cohort Open
Introduction Anticipating the diagnosis of Alzheimer’s disease (AD) at an early asymptomatic at-risk stage, where therapeutics can more effectively delay conscious cognitive decline, is currently among the biggest challenges in the field. …
View article: Perspectives on the diagnosis and management of functional cognitive disorder: An international Delphi study
Perspectives on the diagnosis and management of functional cognitive disorder: An international Delphi study Open
Background Current proposed criteria for functional cognitive disorder (FCD) have not been externally validated. We sought to analyse the current perspectives of cognitive specialists in the diagnosis and management of FCD in comparison wi…
View article: Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia
Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia Open
This comprehensive analysis demonstrated that the variance in AD blood biomarker concentrations was mainly explained by age, with minor contributions from cognition, brain atrophy, and genetics, conversely to CSF measures. These results ch…
View article: Self-Modulation of Gamma-Band Synchronization through EEG-Neurofeedback Training in the Elderly
Self-Modulation of Gamma-Band Synchronization through EEG-Neurofeedback Training in the Elderly Open
Background: Electroencephalography (EEG) stands as a pivotal non-invasive tool, capturing brain signals with millisecond precision and enabling real-time monitoring of individuals’ mental states. Using appropriate biomarkers extracted from…
View article: “Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies
“Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies Open
View article: The association between posterior resting-state EEG alpha rhythms and functional MRI connectivity in older adults with subjective memory complaint
The association between posterior resting-state EEG alpha rhythms and functional MRI connectivity in older adults with subjective memory complaint Open
Resting-state eyes-closed electroencephalographic (rsEEG) alpha rhythms are dominant in posterior cortical areas in healthy adults and are abnormal in subjective memory complaint (SMC) persons with Alzheimer's disease amyloidosis. This exp…
View article: The Memory Binding Test Detects Early Subtle Episodic Memory Decline in Preclinical Alzheimer’s Disease: A Longitudinal Study
The Memory Binding Test Detects Early Subtle Episodic Memory Decline in Preclinical Alzheimer’s Disease: A Longitudinal Study Open
Background: The asymptomatic at-risk phase might be the optimal time-window to establish clinically meaningful endpoints in Alzheimer’s disease (AD). Objective: We investigated whether, compared with the Free and Cued Selective Reminding T…
View article: European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders Open
View article: Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis
Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis Open
None.
View article: Amyloid Reduction and Dementia Progression in Dominantly Inherited Alzheimer's Diseaseafter Long-Term Gantenerumab Treatment: Results from the Dian-Tu Trial
Amyloid Reduction and Dementia Progression in Dominantly Inherited Alzheimer's Diseaseafter Long-Term Gantenerumab Treatment: Results from the Dian-Tu Trial Open
View article: Cerebral amyloid angiopathy frequency at baseline and after 4 years of follow‐up in the INSIGHT‐preAD study
Cerebral amyloid angiopathy frequency at baseline and after 4 years of follow‐up in the INSIGHT‐preAD study Open
Background Cerebral amyloid angiopathy (CAA) diagnostic is of special interest due to its association with cognitive impairment, Alzheimer disease (AD) and Amyloid‐Related Imaging Abnormalities (ARIA) in trials with anti‐amyloid immunother…
View article: The association between Aβ aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort
The association between Aβ aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort Open
Background The present study aimed to explore the association between Apolipoprotein E (APOE) genotype, the main genetic risk factor for sporadic Alzheimer’s Disease (AD), age, and cerebral β‐amyloid (Aβ) aggregation, the earliest patholog…
View article: Differential associations between regional amyloid PET and Alzheimer’s disease polygenic risk scores
Differential associations between regional amyloid PET and Alzheimer’s disease polygenic risk scores Open
Background We previously described three spatio‐temporal subtypes of amyloid accumulation trajectories, measured with PET (Collij et al., 2022). APOE4 carriers tended to have initial amyloid deposition in frontal regions compared to those …
View article: A Centiloid cut‐off to help predict true amyloid accumulation
A Centiloid cut‐off to help predict true amyloid accumulation Open
Background Longitudinal amyloid‐PET‐based imaging endpoints are often included in clinical trials, where they provide critical evidence of treatment efficacy. We assessed the longitudinal variability of the Centiloid (CL) scale and its abi…
View article: The Memory Binding Test: a new tool to assess emerging episodic memory decline in asymptomatic at‐risk individuals to Alzheimer’s disease
The Memory Binding Test: a new tool to assess emerging episodic memory decline in asymptomatic at‐risk individuals to Alzheimer’s disease Open
Background Episodic memory (EM) deficits are a hallmark of Alzheimer’s disease (AD). The Free and Cued Selective Reminding Test (FCSRT) is the most specific official diagnostic tool detecting AD‐linked EM alterations in advanced preclinica…
View article: Event‐related potential signatures of episodic memory decline predicting progression to Alzheimer’s disease in asymptomatic at‐risk subjects: a longitudinal study.
Event‐related potential signatures of episodic memory decline predicting progression to Alzheimer’s disease in asymptomatic at‐risk subjects: a longitudinal study. Open
Background The challenge in Alzheimer’s disease (AD) research ‐the world most prevalent dementia‐remains on finding preclinical markers that can predict progression to the disease. In this respect electrophysiological (EEG) measures seem p…
View article: Amyloid‐PET Centiloid quantification predicts cognitive functioning in a pre‐dementia population: findings from AMYPAD‐PNHS
Amyloid‐PET Centiloid quantification predicts cognitive functioning in a pre‐dementia population: findings from AMYPAD‐PNHS Open
Background The prevention of symptomatic Alzheimer’s disease (AD) is a major endeavor currently in the field, with the prevalence of subjects on the AD continuum (i.e. presence of amyloid‐β [Aβ] pathology) being much higher than previously…
View article: Amyloid‐PET Centiloid quantification predicts cognitive functioning in a pre‐dementia population: findings from AMYPAD‐PNHS
Amyloid‐PET Centiloid quantification predicts cognitive functioning in a pre‐dementia population: findings from AMYPAD‐PNHS Open
Background The prevention of symptomatic Alzheimer’s disease (AD) is a major endeavor currently in the field, with the prevalence of subjects on the AD continuum (i.e. presence of amyloid‐ß [Aß] pathology) being much higher than previously…
View article: A Centiloid cut‐off to help predict true amyloid accumulation
A Centiloid cut‐off to help predict true amyloid accumulation Open
Background Longitudinal amyloid‐PET‐based imaging endpoints are often included in clinical trials, where they provide critical evidence of treatment efficacy. We assessed the longitudinal variability of the Centiloid (CL) scale and its abi…